Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.Canada Sleep Apnea Devices Market was valued at USD 338.54 Million in 2023 and is expected to reach USD 465.53 Million by 2029 with a CAGR of 5.41% The Canada Sleep Apnea Devices Market is being driven by several key factors. The increasing prevalence of sleep apnea, fueled by rising obesity rates and an ag ...

Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estima ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is mad ...

ResMed Inc.’s (RMD) growth in the first quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its Device sales continue to drive overall revenue growth, driven by the combined availability of Airsense10 and Airsense11. The company’s investment in newer-to-market technologies within its Respiratory Care product space looks encouraging. However, the increasing debt burden on ResMed’s operations remains a concern.  In the past year, shares of this Zacks Rank #1 (Strong Buy) c ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style ...

Shares of ResMed (RMD) have been strong performers lately, with the stock up 7.1% over the past month. The stock hit a new 52-week high of $260.49 in the previous session. ResMed has gained 48.9% since the start of the year compared to the 5.1% move for the Zacks Medical sector and the 12.8% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last fo ...

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business. Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio ...

ResMed Inc.’s (RMD) adjusted earnings per share (EPS) in the first quarter of fiscal 2025 were $2.20, up 34.1% year over year. The metric beat the Zacks Consensus Estimate by 8.4%.The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, along with the income tax effect on those adjustments.GAAP EPS in the reported quarter was $2.11, up 41.6% from the year-ago level.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the annou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.004 per share RMD New York Stock Exchange FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT ...